SCHEMBL2675563

SCHEMBL2675563

O=C(O)c1c(CN2CCN(CCCN3CCOCC3)CC2)n(-c2ccccc2)c(=O)c2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 5/20 0.48
TSHR P16473 1/20 0.48
LMNA P02545 4/20 0.45
GAA P10253 2/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
ALDH1A1 P00352 4/20 0.45
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42
HTR7 P34969 3/20 0.42
HTR1A P08908 1/20 0.42
POLB P06746 1/20 0.42
SHMT2 P34897 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
ABCB1 P08183 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676679 0.97 NPSR1 (0.50) NPSR1TSHRLMNAGAAMAPT
SCHEMBL2676684 0.93 NPSR1 (0.53) NPSR1TSHRLMNAGAAMAPT
SCHEMBL2675842 0.90 HRH3 (0.43) NPSR1MAPTALDH1A1HSD17B10KMT2A
SCHEMBL2675909 0.90 ABCB1 (0.52) NPSR1TSHRLMNAGAAMAPT
SCHEMBL2676725 0.90 HTR3A (0.47) NPSR1TSHRLMNAGAAMAPT
SCHEMBL2677086 0.89 HRH3 (0.45) LMNAMAPTALDH1A1HSD17B10KMT2A
SCHEMBL2675946 0.88 P4HB (0.45) NPSR1MAPTALDH1A1MAPK1SMN1; SMN2
SCHEMBL2675259 0.88 ALDH1A1 (0.46) NPSR1TSHRLMNAGAAMAPT
SCHEMBL2677561 0.88 ALDH1A1 (0.42) NPSR1TSHRLMNAMAPTALDH1A1
SCHEMBL2676931 0.87 AKR1C3 (0.50) NPSR1TSHRLMNAGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 NPSR1 182/4885TSHR 1227/4885LMNA 4207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.